Home › Research › Biomarkers
Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment
Jeong SH, Kim HR, Kim J, Kim H, Hong N, Jung JH, Baik K, Cho H et al.. Neurology, 2021-08-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and objective To investigate whether dipeptidyl peptidase-4 inhibitors (DPP-4i) have beneficial effects on amyloid aggregation and longitudinal cognitive outcome in diabetic Alzheimer disease-related cognitive impairment (ADCI). Methods We retrospectively reviewed 282 patients with ADCI with positive 18 F-florbetaben amyloid PET images. Patients were classified into 3 groups according to prior diagnosis of diabetes and DPP-4i use: diabetic patients being treated with (ADCI-DPP-4i + , n = 70) or without DPP-4i (ADCI-DPP-4i - , n = 71) and nondiabetic patients (n = 141). Multiple linear regression analyses were performed to determine intergroup differences in global and regional amyloid retention using standardized uptake value ratios calculated from cortical areas. We assessed longitudinal changes in Mini-Mental State Examination (MMSE) score using a linear mixed model. Results The ADCI-DPP-4i + group had lower global amyloid burden than the ADCI-DPP-4i - group (β = 0.075, SE = 0.024, p = 0.002) and the nondiabetic ADCI group (β = 0.054, SE = 0.021, p = 0.010) after adjusting for age, sex, education, cognitive status, and APOE ε4 carrier status. The ADCI-DPP-4i + group had lower regional amyloid burden in temporo-parietal areas than either the ADCI-DPP-4i - group or the nondiabetic ADCI group. The ADCI-DPP-4i + group showed a slower longitudinal decrease in MMSE score (β = 0.772, SE = 0.272, p = 0.005) and memory recall subscore (β = 0.291, SE = 0.116, p = 0.012) than the ADCI-DPP-4i - group. Discussion These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 70 participants. In a review of 282 patients with diabetes and Alzheimer-related cognitive impairment, those taking DPP-4 inhibitors had lower amyloid burden on PET scans and a slower decline in MMSE scores than those not taking them. This is an observational association and does not prove that DPP-4 inhibitors treat or prevent Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jeong, S. H., Kim, H. R., Kim, J., Kim, H., Hong, N., Jung, J. H., et al. (2021). Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment. Neurology. https://doi.org/10.1212/wnl.0000000000012534
Vancouver
Jeong SH, Kim HR, Kim J, Kim H, Hong N, Jung JH, et al. Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment. Neurology. 2021. doi:10.1212/wnl.0000000000012534. PMID: 34380754.
BibTeX
@article{jeong2021-34380754,
author = {Jeong, S. H. and Kim, H. R. and Kim, J. and Kim, H. and Hong, N. and Jung, J. H. and Baik, K. and Cho, H. and others},
title = {{Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment}},
journal = {Neurology},
year = {2021},
doi = {10.1212/wnl.0000000000012534},
pmid = {34380754},
url = {https://doi.org/10.1212/wnl.0000000000012534}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The ADCI-DPP-4i + group had lower global amyloid burden than the ADCI-DPP-4i - group (β = 0.075, SE = 0.024, p = 0.002) and the nondiabetic ADCI group (β = 0.054, SE = 0.021, p = 0.010) after adjusting for age, sex, education, cognitive status, and APOE ε4 carrier status.
- Discussion These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI.
Why it matters
In a review of 282 patients with diabetes and Alzheimer-related cognitive impairment, those taking DPP-4 inhibitors had lower amyloid burden on PET scans and a slower decline in MMSE scores than those not taking them. This is an observational association and does not prove that DPP-4 inhibitors treat or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants70
- Evidence strengthModerate
How this study scored 58/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 70 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 29 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.1 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 3 / 6 | Cited 3.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Phil Hyu Lee: h-index 61 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Yonsei University: institution h-index 777 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34380754) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000012534
- PubMed: 34380754
- Original source →
- Free full text: n.neurology.org →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.